{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:13:36Z","timestamp":1785165216591,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allergic rhinitis (AR) is a prevalent chronic inflammatory disorder characterized by persistent inflammation and nasal epithelial barrier disruption. Restoring epithelial integrity and modulating the inflammatory cascade are considered promising therapeutic strategies for AR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to systematically investigate the therapeutic efficacy of Yuping Tongqiao Tablet (YPTQ), a traditional Chinese medicine formula, in the treatment of AR and to decipher its potential mechanisms and active ingredients focusing on inflammation amelioration and barrier restoration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An AR model was established in Sprague-Dawley rats that were sensitized and challenged with OVA. After intervention with different doses of YPTQ, nasal pathological injury and inflammatory cell infiltration were evaluated.\n                      <jats:italic>In vitro<\/jats:italic>\n                      , a human nasal epithelial cell (RPMI-2650) injury model was induced using house dust mites (HDM). Following YPTQ treatment, the expression levels of inflammatory factors and barrier-related proteins were assessed. Furthermore, the potential mechanisms and targets of YPTQ and its active monomers against AR were investigated by integrating network pharmacology analysis and molecular docking with\n                      <jats:italic>in vitro<\/jats:italic>\n                      experiments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the OVA-induced AR rat model, YPTQ effectively alleviated nasal symptoms, reduced histopathological damage and inflammatory cell infiltration, and suppressed overall inflammatory levels. In the HDM-induced RPMI-2650 cell injury model, YPTQ significantly inhibited inflammatory cytokines release and upregulated the tight junction protein ZO-1, thereby enhancing epithelial barrier function. Moreover, integrated analysis combining network pharmacology, molecular docking, and both\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      validation confirmed that YPTQ and its active ingredient, kaempferol, exert therapeutic effects through two main pathways. Firstly, they down-regulated the expression of TSLP and inhibited the migration of DCs, which subsequently alleviated nasal inflammation. Secondly, they up-regulated and activated the expression of AhR and the downstream CYP1A1, which in turn promoted the expression of a barrier-associated protein, contributing to the restoration of nasal epithelial barrier integrity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1824120","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:00Z","timestamp":1778219460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-targeted protection of Yuping Tongqiao against allergic rhinitis: suppression of inflammatory response via TSLP signaling and reinforcement of epithelial barrier integrity via AhR signaling"],"prefix":"10.3389","volume":"7","author":[{"given":"Zhixin","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]},{"name":"Graduate School, Hebei University of Chinese Medicine","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine School of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zheng","sequence":"additional","affiliation":[{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Tong","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Hou","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]},{"name":"Graduate School, Hebei University of Chinese Medicine","place":["Shijiazhuang, Hebei, China"]},{"name":"Shanghai Yiling Pharmaceutical Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Jia","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]},{"name":"High-level TCM Key Disciplines of National Administration of Traditional Chinese Medicine \u2013 Luobing Theory, Hebei Yiling Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qi","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Innovation and Transformation of Luobing Theory","place":["Shijiazhuang, Hebei, China"]},{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis\u20142023","volume":"13","author":"Wise","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/s41591-025-03651-5","article-title":"Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/lary.30129","article-title":"Demographic disparities in the federal drug approval process for allergic rhinitis medications","volume":"133","author":"Liebowitz","year":"2023","journal-title":"Laryngoscope"},{"key":"B4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4168\/aair.2022.14.6.604","article-title":"Chinese Guideline on allergen immunotherapy for allergic rhinitis: the 2022 update","volume":"14","author":"Wang","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2500\/ajra.2016.30.4253","article-title":"The role of allergen immunotherapy in the management of allergic rhinitis","volume":"30","author":"Cox","year":"2016","journal-title":"Am J Rhinol Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.jacig.2026.100664","article-title":"Multidimensional characterization of allergic rhinitis in mysuru, south India: a cluster-based approach","volume":"5","author":"Mahesh","year":"2026","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1509552","DOI":"10.3389\/falgy.2024.1509552","article-title":"Risk factors of allergic rhinitis and its prevention strategies","volume":"5","author":"Chen","year":"2024","journal-title":"Front Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2500\/ajra.2016.30.4391","article-title":"Combination therapy in allergic rhinitis: what works and what does not work","volume":"30","author":"Greiwe","year":"2016","journal-title":"Am J Rhinol Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jama.2024.0530","article-title":"Allergic rhinitis: a review","volume":"331","author":"Bernstein","year":"2024","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"874114","DOI":"10.3389\/fmed.2022.874114","article-title":"Allergic rhinitis: a clinical and pathophysiological overview","volume":"9","author":"Nur Husna","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"117738","DOI":"10.1016\/j.biopha.2024.117738","article-title":"Interleukin-38-overexpressing adenovirus infection in dendritic cell-based treatment enhances immunotherapy for allergic asthma via inducing Foxp3(+) regulatory T cells","volume":"181","author":"Chuang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"114439","DOI":"10.1016\/j.intimp.2025.114439","article-title":"Macrophage-mediated activation of the IL4I1\/AhR axis is a key player in allergic rhinitis","volume":"152","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"138145","DOI":"10.1016\/j.jhazmat.2025.138145","article-title":"PM(2.5) exacerbates nasal epithelial barrier dysfunction in allergic rhinitis by inducing NLRP3-mediated pyroptosis via the AhR\/CYP1A1\/ROS axis","volume":"492","author":"Yuan","year":"2025","journal-title":"J Hazard Mater"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/s41467-024-45473-y","article-title":"Porphyromonas gingivalis aggravates colitis via a gut microbiota-linoleic acid metabolism-Th17\/treg cell balance axis","volume":"15","author":"Jia","year":"2024","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1142\/S0192415X23500374","article-title":"Traditional Chinese herbal medicine for allergic diseases: a review","volume":"51","author":"Ai","year":"2023","journal-title":"Am J Chin Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"119574","DOI":"10.1016\/j.jep.2025.119574","article-title":"Safety and onset time of modified yupingfeng nasal spray versus mometasone furoate nasal spray on house dust mites-induced moderate to severe allergic rhinitis: a prospective, multicenter, randomized, open-label, parallel-group clinical trial","volume":"344","author":"Wang","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e26929","DOI":"10.1097\/MD.0000000000026929","article-title":"Mechanisms and molecular targets of the yu-ping-feng powder for allergic rhinitis, based on network pharmacology","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"120091","DOI":"10.1016\/j.jep.2025.120091","article-title":"A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of yuping tongqiao tablets in the treatment of persistent allergic rhinitis","volume":"351","author":"Wang","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12951-024-02306-w","article-title":"Long-acting anti-inflammatory injectable DEX-gel with sustained release and self-healing properties regulates T(H)1\/T(H)2 immune balance for minimally invasive treatment of allergic rhinitis","volume":"22","author":"Dai","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"154516","DOI":"10.1016\/j.phymed.2022.154516","article-title":"ESP-B4 promotes nasal epithelial cell-derived extracellular vesicles containing miR-146a-5p to modulate Smad3\/GATA-3 thus relieving allergic rhinitis: eSP-B4\/miR-146a-5p in AR","volume":"108","author":"Li","year":"2023","journal-title":"Phytomedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/jcb.22511","article-title":"House dust mite extract activates apical cl(-) channels through protease-activated receptor 2 in human airway epithelia","volume":"109","author":"Cho","year":"2010","journal-title":"J Cell Biochem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2050009","DOI":"10.1142\/S0219720020500092","article-title":"PDB-2-PBv3.0: an updated protein block database","volume":"18","author":"Karuppasamy","year":"2020","journal-title":"J Bioinform Comput Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","article-title":"Pubchem 2025 update","volume":"53","author":"Kim","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jep.2018.12.033","article-title":"Exploring the multicomponent synergy mechanism of banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy","volume":"233","author":"Li","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and autodock\/vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J Comput Aided Mol Des"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.xpro.2022.101664","article-title":"Protocol to isolate and analyze mouse bone marrow derived dendritic cells (BMDC)","volume":"3","author":"Sauter","year":"2022","journal-title":"STAR Protoc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103162","DOI":"10.1016\/j.jaut.2023.103162","article-title":"Silencing of aryl hydrocarbon receptor repressor restrains Th17 cell immunity in autoimmune hepatitis","volume":"143","author":"Gao","year":"2024","journal-title":"J Autoimmun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12951-024-02748-2","article-title":"New insights into allergic rhinitis treatment: mSC nanovesicles targeting dendritic cells","volume":"22","author":"Liu","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1348272","DOI":"10.3389\/fimmu.2024.1348272","article-title":"Involvement and repair of epithelial barrier dysfunction in allergic diseases","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"104566","DOI":"10.1016\/j.amjoto.2024.104566","article-title":"Efficacy of combination therapy with mometasone and montelukast versus mometasone alone in treatment of adenoid hypertrophy in children: a systematic review and meta-analysis","volume":"46","author":"Joseph","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1651-2227.2009.01351.x","article-title":"Anti-inflammatory treatment of asthma: differentiation and trial-and-error","volume":"98","author":"Wolthers","year":"2009","journal-title":"Acta Paediatr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1172\/JCI8624","article-title":"Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4","volume":"105","author":"Herrick","year":"2000","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.it.2018.10.010","article-title":"The aryl hydrocarbon receptor: connecting immunity to the microenvironment","volume":"39","author":"Shinde","year":"2018","journal-title":"Trends Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1057555","DOI":"10.3389\/fimmu.2022.1057555","article-title":"Aryl hydrocarbon receptor: the master regulator of immune responses in allergic diseases","volume":"13","author":"Riaz","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"157065","DOI":"10.1016\/j.phymed.2025.157065","article-title":"Shenling tongqiao powder targets TGF-beta1\/smad-wnt\/beta-catenin axis to suppress epithelial-mesenchymal transition in chronic rhinosinusitis","volume":"145","author":"Liu","year":"2025","journal-title":"Phytomedicine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"157620","DOI":"10.1016\/j.phymed.2025.157620","article-title":"Laminaria japonica extract alleviates fine particulate matter-exacerbated allergic rhinitis by inhibiting NLRP3-mediated pyroptosis and restoring epithelial barrier function","volume":"150","author":"Zhang","year":"2025","journal-title":"Phytomedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"101342","DOI":"10.1016\/j.jpha.2025.101342","article-title":"Quantifying compatibility mechanisms in traditional Chinese medicine with interpretable graph neural networks","volume":"15","author":"Zeng","year":"2025","journal-title":"J Pharm Anal"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1824120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:02Z","timestamp":1778219462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1824120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":41,"alternative-id":["10.3389\/falgy.2026.1824120"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1824120","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1824120"}}